$RGLS,,,this stock has stayed on my watchlist for the past eight months. I play it whenever I see it provide an opportunity to make a few dollars. I believe we might see RGLS give us that opportunity some time this week. Apparently it has had a lot of insiders buying stock lately. Of course, and as you can see below, the price they paid is much lower than than the current price. Director Papadopolous bought quite a few shares for himself. The shares were purchased on the 25th and the stock gapped from $1.11 to 1.22 at the opening on the 26th. The shares traded upwards of $1.26 but as the week wore on, the price dropped and at the closing on Friday the pps was a Paltry $1.02. The volume on Friday was impressive as it was double the average daily volume. The RSI and the MFI are showing this stock is oversold, however the MACD and stochastics are showing me the price may still drop a bit before turning. I will be keeping my eye on this during the week.
GuruFocus.comJuly 25, 2017
- By insider
President and CEO of Regulus Therapeutics Inc (RGLS) Joseph P Hagan bought 219,780 shares of RGLS on 07/25/2017 at an average price of $0.91 a share. The total cost of this purchase was $200,000.
Regulus Therapeutics Inc is a biotechnology company that focuses on the development of microRNA therapies. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. Regulus Therapeutics Inc has a market cap of $59.030 million; its shares were traded at around $1.11 with and P/S ratio of 85.39.
CEO Recent Trades:
President and CEO Joseph P Hagan bought 219,780 shares of RGLS stock on 07/25/2017 at the average price of $0.91.
CFO Recent Trades:
CFO Daniel R. Chevallard bought 54,945 shares of RGLS stock on 07/25/2017 at the average price of $0.91.
Directors and Officers Recent Trades:
Chief R & D Officer Timothy Michael Wright bought 274,725 shares of RGLS stock on 07/25/2017 at the average price of $0.91.
Director William H Rastetter bought 274,725 shares of RGLS stock on 07/25/2017 at the average price of $0.91.
Director Stelios Papadopoulos bought 1,000,000 shares of RGLS stock on 07/25/2017 at the average price of $0.91.
GuruFocus.comJuly 25, 2017
- By insider
President and CEO of Regulus Therapeutics Inc (RGLS) Joseph P Hagan bought 219,780 shares of RGLS on 07/25/2017 at an average price of $0.91 a share. The total cost of this purchase was $200,000.
Regulus Therapeutics Inc is a biotechnology company that focuses on the development of microRNA therapies. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. Regulus Therapeutics Inc has a market cap of $59.030 million; its shares were traded at around $1.11 with and P/S ratio of 85.39.
CEO Recent Trades:
President and CEO Joseph P Hagan bought 219,780 shares of RGLS stock on 07/25/2017 at the average price of $0.91.
CFO Recent Trades:
CFO Daniel R. Chevallard bought 54,945 shares of RGLS stock on 07/25/2017 at the average price of $0.91.
Directors and Officers Recent Trades:
Chief R & D Officer Timothy Michael Wright bought 274,725 shares of RGLS stock on 07/25/2017 at the average price of $0.91.
Director William H Rastetter bought 274,725 shares of RGLS stock on 07/25/2017 at the average price of $0.91.
Director Stelios Papadopoulos bought 1,000,000 shares of RGLS stock on 07/25/2017 at the average price of $0.91.
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
